[Breaking NEWS] Thousand Oaks Biopharmaceuticals helping Gmax Biopharm obtain clinical trial approval for the first antibody PAH drug in China

Recently, GMA301, a recombinant monoclonal antibody drug targeting to human endothelin receptor A, developed by Gmax Biopharm LLC, has been approved for clinical trials in China for the treatment of Pulmonary Arterial Hypertension (PAH). Thousand Oaks Biopharmaceuticals hereby extend our warm congratulations.

As an important partner of Gmax Biopharm, Thousand Oaks Biopharmaceuticals provided comprehensive services in the GMA301 project from cell line development to process optimization and batch production for clinical submission, which has been highly recognized by the customer. Thousand Oaks Biopharmaceuticals is still improving product processes and has increased the protein expression quantity by 5 times so far.

GMA301 is the first antibody drug targeting to endothelin receptor A for the treatment of pulmonary arterial hypertension, and is developed by Gmax Biopharm on its independently constructed G protein-coupled receptor (GPCR) antibody technology platform. At present, the drug has gone through the phase I a clinical trial in Australia, and the application for clinical trial registration in the United States has also been submitted. Multi-center clinical trial will be carried out in China and the United States shortly.